Warnex Inc.

Warnex Inc.

February 20, 2006 07:00 ET

Warnex first to launch quantitative PCR test for food testing

LAVAL, QC, Feb. 20 - Warnex Inc. (TSX:WNX) announced today the
launch of a quantitative test for Campylobacter for use with the real-time
PCR-based Warnex™ Rapid Pathogen Detection System. With no enrichment
required, this test detects and quantifies Campylobacter in poultry rinses
within 3 hours. This is the first PCR-based test available to the food
industry that quantifies the amount of Campylobacter present in a sample.

"Given the prevalence of Campylobacter infections from food, particularly
poultry, there is an increasing need for rapid tests that detect this
pathogen," said Mark Busgang, President and CEO of Warnex. "For instance, in
Europe, new regulations for decreasing the incidence of Campylobacter
infection are imminent. Our test, which detects and quantifies this pathogen,
can be instrumental in assisting food companies in improving the safety of
their products."

According to the Centers for Disease Control and Prevention (CDC),
Campylobacter is one of the most common bacterial causes of diarrheal illness
in the United States, with an estimated 2.4 million cases every year. In
addition to diarrhea, Campylobacter infections cause cramping, abdominal pain,
and fever, and may occasionally cause a serious life-threatening infection for
persons with weakened immune systems. Warnex's Campylobacter test detects and
quantifies three species of this pathogen, Campylobacter jejuni, C. coli and
C. lari, which account for 99% of reported Campylobacter illness cases.

"This achievement of being first to market with a quantitative
Campylobacter test underscores the strength of our technology and expertise,"
said Dr. Yvan Côté, Vice President, Research & Development. "This test is the
first in our strategy to produce a series of real-time PCR quantification
tests."

Warnex's quantitative Campylobacter test will be commercially available
in April 2006.

Warnex also announced today that three more of its tests have been
granted "Laboratory Procedure" status by Health Canada, following independent
validations by the Canadian Food Inspection Agency (CFIA). These tests include
one for E. coli O157:H7 and two semi-quantitative tests for generic E. coli
and Staphylococcus aureus. These semi-quantitative tests not only detect the
presence of the bacteria, but also indicate whether they are present beyond a
user-defined threshold. The test procedures can be found in Volume 3 of the
Health Canada Compendium of Analytical Methods, or at
http://www.hc-sc.gc.ca/fn-an/res-rech/analy-meth/microbio/volume3/index_e.html

About Warnex

Warnex (www.warnex.ca) is a biotechnology company devoted to protecting
public health by providing advanced diagnostic products and science-based
services to the agri-food, pharmaceutical and healthcare sectors. Warnex's
genomics-based technology offers a versatile detection platform that produces
accurate results rapidly, using Real-Time PCR technology combined with unique
genetic markers and software. With a focus on pathogen detection in food, our
development pipeline also includes applications in GMO testing, meat
speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex's analytical, bioanalytical, and clinical service groups offer a
variety of quality control services, method development and validation,
contract R&D, bioavailability and bioequivalence studies for clinical trials,
and medical laboratory testing.

Warnex is a trademark of Warnex Inc.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, manufacturing and laboratory facilities, suppliers,
key employees, key customers, financial resources and credit risk, government
regulations, foreign currency risk and volatility of share price, and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to the
heading Risks and Uncertainties in the Management's Discussion and Analysis
for the third quarter ended on September 30, 2005, which can be found at
www.sedar.com. Consequently, actual results may differ materially from the
anticipated results expressed in these forward-looking statements.

Contact Information